Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: SGLT2i May 05 | 2022DELIVER Delivers for AZ; Priority Review Depends on CV DeathPurchase Blast
$599
Posted in: Glucose Monitoring, Other May 03 | 2022Lilly and Genesis Therapeutics Collaboration; Esperion Q1 ’22 Earnings Update; Oramed’s Pivotal Ph3 Oral Insulin Trial Completes Enrollment; MySugarWatch Launches HCP-focused Ad Campaign for sugarBEAT in MIMSPurchase Blast
$599
Posted in: Insulin Delivery, Other May 02 | 2022Beta Bionics Insulin-only iLet Pivotal Trial Results @ ATTD 2022; Vertex's Ph1/2 VX-880 Trial Placed on Clinical HoldPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Apr 29 | 2022Novo, Dexcom, AZ, Sanofi, Biocon, and Teladoc Q1 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin Apr 28 | 2022Novo Reports First QW Basal Insulin Icodec Ph3 DataPurchase Blast
$599
Posted in: Dual/triple agonist, SGLT2i Apr 28 | 2022Did Lilly Cure Obesity? SURMOUNT-1 Topline Results; Q1 ‘22 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Apr 28 | 2022ATTD 2022 Key Press Releases (April 27); Abbott, Ypsomed, and CamDiab to develop AID SystemPurchase Blast
$599
Posted in: Glucose Monitoring Apr 20 | 2022Abbott Q1 ’22 Earnings Update; New YouTube Video Featuring Libre 2 AppPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, SGLT2i Apr 19 | 2022Daprodustat NDA Accepted by FDA; Sean Saint Looks to Do It Again; April 19-22 CHMP Agenda; J&J Q1 ’22 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, SGLT2i Apr 14 | 2022New Medtronic 780G + Lyumjev Trial; Xigduo XR DAPA-CKD sNDA approved; Galectin NASH Trial to Continue; Sciwind Initiates Ph1 Oral GLP-1RA TrialPurchase Blast
$599
Posted in: Basal Insulin, Other Apr 13 | 2022Viatris Glargine Recalled; Carbon Health Launches Diabetes Management ProgramPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Apr 12 | 2022Apple Watch Reportedly Faces Glucose Monitoring Delays; Diabeloop to Adapt AID Software for Insulin Pens; MediciNova to Initiate Ph2 NAFLD TrialPurchase Blast
$599
Posted in: Other Apr 06 | 2022Merck Hosts Investor Event Highlighting CV Portfolio and PipelinePurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Apr 04 | 2022AZ/Ionis Ph2b Data @ ACC 2022; Novartis Restructures Pharma Business; Eversense E3 Launched in the US; Dexcom ONE to Launch in UK; New Sota and Kerendia Subanalyses @ ACC 2022; Fractyl Receives IDE for Second Pivotal TrialPurchase Blast
$599
Posted in: Other Mar 31 | 2022Daprodustat US approval in question after vada CRL; Akebia post-CRL investor call highlightsPurchase Blast
$599
Posted in: Glucagon, Other Mar 30 | 2022Zealand Restructures Business to Focus on R&D and Cuts 90% of US Workforce; Samsung and JDRF T1DM Invest in Jaguar Gene TherapyPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Mar 29 | 2022Lannett Initiates Bs-glargine Pivotal Trial; Tirzepatide Meta-analysis Shows No Increased MACE Risk in T2DM; Provention Bio’s PRV-101 Vaccine Positive Final ResultsPurchase Blast